Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

Exact Sciences Announces Second Quarter 2022 Results

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer